Azerbaijan

Healthcare & Pharmaceutical Market

Strategically positioned between Europe, the Caucasus, Central Asia, and the Middle East, Azerbaijan represents a growing pharmaceutical and healthcare market with expanding opportunities in specialty care and innovative therapies.

With ongoing healthcare modernization initiatives, increasing focus on innovative treatments, and a developing reimbursement ecosystem, Azerbaijan is becoming an increasingly attractive market for international pharmaceutical and biotechnology companies seeking regional growth opportunities.

Why Azerbaijan?

1. Strong and Stable Market Fundamentals

According to recent industry data and national forecasts, Azerbaijan demonstrates a robust macroeconomic and healthcare environment:

• Population: 10.4 million (2025)

• Azerbaijan pharmaceutical market: $810 M, with ~18% annual growth

• Public reimbursement share: 40% and expanding under SAMHI

• Universal insurance coverage

• Healthcare spending: 4.7% of GDP

• GDP per capita (2025 forecast): $7,370

• Stable currency: 1.7 AZN/USD, unchanged for over 7 years

• Inflation rate: 5.9% (moderate and controlled)

• Ambitious state investment into modernization of hospitals and clinical services

These fundamentals position Azerbaijan as a predictable, stable environment for long-term pharmaceutical partnerships.

2. A Healthcare System Driven by Rapid Reform

The introduction and expansion of Mandatory Health Insurance (SAMHI) has been the most transformative driver of the sector:

Key institutions shaping pharmaceutical access:

• SAMHI – reimbursement & access decision-maker

• Ministry of Health (MoH) – regulatory authority

• CAE (Center for Analytics & Expertise) – scientific evaluation of dossiers

• TABIB – centralized procurement for public hospitals

• Tariff Council – wholesale/retail price approvals

This coordinated framework ensures transparency and predictability across pricing, registration, public listing, and hospital access.

3. Structured and Predictable Pricing System

Azerbaijan operates a regulated reference pricing model, with all prices approved by the Tariff Council at both wholesale and pharmacy levels. This provides manufacturers with:

• Clear price calculation methodology

• Alignment with international reference markets

• Stability for long-term commercial planning

• Centralized publication of approved prices

The pricing system is aligned with Resolution No. 209 dated May 3, 2019. The official Azerbaijani version of the resolution is available here.

You can also download the English version of the pricing calculationhere

4. Efficient Regulatory Pathways with Fast-Track Options

The regulatory environment provides clearly defined, efficient routes to market:

Standard regulatory pathway

• 8–12 months: dossier evaluation by CAE → MoH approval → price approval

• 1–2 months: private market launch
  

Fast-track pathway for Orphan Drugs

• Exempt from standard regulatory timelines

• Based on EMA or FDA orphan designation

• Recognized via dedicated regulation
  

This accelerated pathway improves access for rare disease therapies.

5. High Demand in Innovative, Specialty and Hospital Segments

Azerbaijan shows growing demand for therapies in:

• Hematology

• Endocrinology

• Neurology & psychiatry

• Pulmonology

• Nephrology & dialysis and other disease areas
  

Limited availability of advanced biologics, and expanding public insurance coverage create a favorable environment for international manufacturers.

6. Strong Distribution & Pharmaceutical Infrastructure

Azerbaijan has a modern, nationwide distribution network supported by GDP-compliant warehousing and cold-chain capabilities.

The country provides reliable last-mile access to thousands of pharmacies and hundreds of healthcare facilities, ensuring national coverage for both retail and hospital segments.

7. Strategic Geography & Regional Expansion Potential

Azerbaijan’s location creates natural access to:

• Caucasus region (Georgia)

• Central Asia (Kazakhstan, Uzbekistan)

• Türkiye & Middle East

• CIS countries

8. Why Enter the Market Now?

• 40% growth in SAMHI budget since 2020

• Fast orphan pathway (EMA/FDA recognition)

• Stable currency for 7+ years

• High demand for specialty & innovative drugs

• Low biosimilar competition

• Healthcare system expansion driven by government policy
  

Together, these factors create an exceptional entry window for global manufacturers.

Azerbaijan Is an Underpenetrated, And Evolving Pharmaceutical Market

With a combination of strong healthcare reforms, predictable pricing, efficient regulation, expanding reimbursement, and significant unmet medical needs, Azerbaijan offers a unique opportunity for global pharmaceutical and biotech companies.

Looking for a trusted local partner in Azerbaijan?

Nexa Pharm provides strategic and operational support across:

• Regulatory Affairs

• Market Access & Commercialization

• Stakeholder Engagement

• Medical & Educational Activities

• Specialty Care and Innovative Therapies